Latest Regulatory News

A1 Investments & Resources Ltd reports a modest cash outflow for the June 2024 quarter while actively pursuing acquisitions and planning convertible note funding to support growth.

Clara Resources outlines key progress on its Ashford Coking Coal Project drilling preparations and details ongoing capital management initiatives, including rights issues and entitlement offers, while navigating boardroom challenges.

Alterity Therapeutics has reported positive Phase 2 results for ATH434, showing significant slowing of Multiple System Atrophy progression and a favorable safety profile. The trial demonstrated clinical benefits alongside reductions in brain iron accumulation, a key disease driver.

Paradigm Biopharmaceuticals has secured FDA clearance for its phase 3 knee osteoarthritis trial and raised $16 million to fund its next clinical steps, positioning the company for a pivotal year ahead.

NSX Limited reports a $1.6 million cash injection from ISXFEU, completes the ClearPay joint venture sale, and reduces operational costs in its 2Q25 activities report, while facing delays in share issuance approval.

Latitude Group Holdings Limited has announced a quarterly distribution of AUD 2.2291 per Capital Note, payable in late April 2025, continuing its steady income stream for investors.

BlinkLab has launched its pivotal FDA registrational study for its AI-driven autism diagnostic app, BlinkLab Dx 1, following positive FDA feedback and promising preliminary results.

Icon Energy Limited reported a $455K cash balance and issued 100 million shares this quarter to sustain operations amid ongoing uncertainty over the ATP 855 permit renewal.

Dome Gold Mines reports steady progress on its Sigatoka industrial sand and magnetite project alongside securing a key government contract for emergency river desilting in Fiji. Exploration results also highlight promising copper and gold anomalies at its Nadroga tenement.

Carbine Resources reports steady progress on its Muchea West silica sand mining licence application, engaging environmental consultants to support upcoming approvals. The company also continues exploration efforts at its Down South project.

Enova Mining has completed a significant drilling campaign at its CODA North project, confirming high-grade rare earth element mineralisation, while securing $1.5 million in new funding to accelerate exploration and metallurgical testing.

Zelira Therapeutics has secured a fourth funding tranche of US$681,000, advancing its HOPE® Autism Spectrum Disorder FDA trial process and bringing total funding to US$3.25 million. The company is progressing clinical validation and product development, including the transformation of Zenivol® into a capsule formulation.